Alternatives to Earendil Labs

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A nonprofit research organization leveraging AI and biotechnology to understand and treat complex diseases.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

Developing oral small molecule medicines for immunological and chronic diseases.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Advancing next-generation mRNA medicines.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on oncology drug discovery.

Immunotherapy company targeting oncology and autoimmune diseases.

Scalable, one-time curative in-vivo gene editing therapies.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Advancing targeted alpha therapies.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

AI-enabled technology for cell biology research and biopharma development.

Space BioTech startup developing an autonomous, high-throughput screening platform for drug discovery in microgravity.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Combines human immune organoid biology with generative AI to reduce immunogenicity risk in antibody development.

AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Advancing biopsy specimen stewardship and expanding access to precision oncology.

Pioneering next-generation bispecific ADCs for cancer treatment.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

A global leader in clinical pharmacology and bioanalytical sciences.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.